1. Home
  2. FLX vs UPB Comparison

FLX vs UPB Comparison

Compare FLX & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLX
  • UPB
  • Stock Information
  • Founded
  • FLX 2013
  • UPB 2021
  • Country
  • FLX China
  • UPB United States
  • Employees
  • FLX N/A
  • UPB N/A
  • Industry
  • FLX
  • UPB
  • Sector
  • FLX
  • UPB
  • Exchange
  • FLX NYSE
  • UPB NYSE
  • Market Cap
  • FLX 619.3M
  • UPB 1.0B
  • IPO Year
  • FLX 2024
  • UPB 2024
  • Fundamental
  • Price
  • FLX $8.30
  • UPB $16.30
  • Analyst Decision
  • FLX
  • UPB Strong Buy
  • Analyst Count
  • FLX 0
  • UPB 4
  • Target Price
  • FLX N/A
  • UPB $56.50
  • AVG Volume (30 Days)
  • FLX 15.8K
  • UPB 460.2K
  • Earning Date
  • FLX 02-27-2025
  • UPB 02-14-2025
  • Dividend Yield
  • FLX N/A
  • UPB N/A
  • EPS Growth
  • FLX N/A
  • UPB N/A
  • EPS
  • FLX 0.19
  • UPB N/A
  • Revenue
  • FLX $663,142,775.00
  • UPB $2,207,000.00
  • Revenue This Year
  • FLX N/A
  • UPB N/A
  • Revenue Next Year
  • FLX N/A
  • UPB N/A
  • P/E Ratio
  • FLX $42.67
  • UPB N/A
  • Revenue Growth
  • FLX 1.31
  • UPB 82.10
  • 52 Week Low
  • FLX $6.50
  • UPB $14.97
  • 52 Week High
  • FLX $21.95
  • UPB $29.46
  • Technical
  • Relative Strength Index (RSI)
  • FLX N/A
  • UPB N/A
  • Support Level
  • FLX N/A
  • UPB N/A
  • Resistance Level
  • FLX N/A
  • UPB N/A
  • Average True Range (ATR)
  • FLX 0.00
  • UPB 0.00
  • MACD
  • FLX 0.00
  • UPB 0.00
  • Stochastic Oscillator
  • FLX 0.00
  • UPB 0.00

About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS

BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).

About UPB UPSTREAM BIO INC

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

Share on Social Networks: